PTPI

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.0018
Percentage change 6.43	%

Peers: AMPH ACRS OKUR VTGN OCUL TVRD CNTX IRD RDHL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-63.15	Insider Own	0.51%	Shs Outstand	31.16M	Perf Week	-2.84%
Market Cap	0.94M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	-	Perf Month	-54.64%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	0.14%	Short Float	-	Perf Quarter	-98.35%
Income	-	P/S	0.18	EPS this Y	-	Inst Trans	-	Short Ratio	0.04	Perf Half Y	-99.76%
Sales	5.11M	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.49M	Perf YTD	-99.69%
Book/sh	-4.67	P/C	-	EPS next 5Y	-	ROE	-	52W High	16.25 -99.81%	Perf Year	-99.71%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	0.02 33.27%	Perf 3Y	-99.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.18% 9.91%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	62.88%	Oper. Margin	-	ATR (14)	0.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	28.48	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-5.80%	Beta	1.76	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-91.66%	Rel Volume	0.08	Prev Close	0.03
Employees	18	LT Debt/Eq	-	Earnings	-	SMA200	-99.41%	Avg Volume	12.08M	Price	0.03
IPO	Dec 02, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% 0.01%	Trades		Volume	997,598	Change	6.43%

May-21-25 09:00AM	Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets (ACCESSWIRE) -46.45%
May-20-25 09:15AM	Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer (ACCESSWIRE) -6.13%
May-06-25 09:20AM	Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform (ACCESSWIRE) -6.64%
May-01-25 09:20AM	Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches (ACCESSWIRE) -10.00%
Apr-29-25 09:20AM	Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms (ACCESSWIRE) -77.55%
09:15AM	Loading…
Mar-20-25 09:15AM	Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications (ACCESSWIRE) +5.85%
Feb-25-25 09:20AM	Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study (ACCESS Newswire)
Feb-18-25 09:25AM	Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants (ACCESSWIRE) -53.48%
Jan-07-25 09:15AM	Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules (ACCESSWIRE)
Dec-19-24 09:15AM	Petros Pharmaceuticals Featured in 'New Era of Healthcare, AI, Data and Consumer Empowerment' (ACCESSWIRE) -11.11%
Dec-17-24 09:00AM	Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually (ACCESSWIRE) +87.27%
Oct-19-24 05:28PM	Petros Pharmaceuticals Amends Presidents Employment Terms (TipRanks)
Sep-11-24 09:15AM	Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) (ACCESSWIRE)
Sep-03-24 09:00AM	Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Aug-16-24 09:53PM	PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
09:20AM	Loading…
Jul-29-24 09:20AM	Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) (ACCESSWIRE)
Jul-16-24 09:00AM	Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance (ACCESSWIRE) -6.23%
May-29-24 09:00AM	Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch (ACCESSWIRE)
May-21-24 09:15AM	Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA (ACCESSWIRE)
May-16-24 10:53AM	PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.30%
May-14-24 09:15AM	Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe (ACCESSWIRE)
07:00AM	Lemonaid Health Now Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals (GlobeNewswire)
Apr-25-24 10:20AM	Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health (News Direct)
Apr-23-24 09:15AM	Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health (ACCESSWIRE)
Apr-16-24 09:15AM	Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) (ACCESSWIRE) -9.97%
Apr-02-24 09:53AM	PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -23.57%
09:15AM	Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status (ACCESSWIRE)
Mar-19-24 09:00AM	Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider (ACCESSWIRE)
Mar-11-24 07:00AM	BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc (News Direct)
Feb-14-24 09:15AM	Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider (ACCESSWIRE)
09:15AM	Loading…
Jan-24-24 09:15AM	Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch (ACCESSWIRE) -8.00%
Jan-17-24 09:00AM	Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch (ACCESSWIRE)
Dec-12-23 10:00AM	Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status (ACCESSWIRE) +7.33%
09:15AM	Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestors (rosuvastatin) OTC Switch Technology Provider (ACCESSWIRE)
Dec-05-23 09:15AM	Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider (ACCESSWIRE)
Oct-30-23 09:15AM	Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R) (ACCESSWIRE)
Oct-19-23 09:00AM	Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA (ACCESSWIRE)
Oct-04-23 09:00AM	Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label (ACCESSWIRE) -8.82%
Sep-28-23 08:00AM	Petros Pharmaceuticals to Present at the LD Micro Main Event XVI (ACCESSWIRE)
Sep-11-23 09:00AM	Petros Pharmaceuticals Provides Letter to Shareholders (ACCESSWIRE) +6.21%
Sep-06-23 04:05PM	Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Jul-13-23 04:30PM	Petros Pharmaceuticals Announces Capital Raise of $15 Million (ACCESSWIRE) -6.60% -10.03%
Nov-30-22 12:45PM	Petros Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE)
Nov-15-22 08:00AM	Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update (ACCESSWIRE)
Oct-25-22 09:00AM	New FDA-Approved Labeling for Petros Pharmaceuticals STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy (ACCESSWIRE) +38.81%
Oct-21-22 08:00AM	Petros Pharmaceuticals to Participate in Two October 2022 Conferences (ACCESSWIRE)
Aug-15-22 08:00AM	Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 (ACCESSWIRE)
Jul-28-22 10:27AM	Petros Pharmaceuticals Responds to Fraudulent Press Release (GlobeNewswire)
09:25AM	Petros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per share (GlobeNewswire)
Jul-19-22 09:15AM	Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky (GlobeNewswire)
May-16-22 05:00PM	Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 09:23AM	Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Companys Novel Topical Investigational Treatment for Peyronies Disease Which Impacts More Than 1 in 10 Men in the US (GlobeNewswire) +7.21%
Apr-27-22 09:25PM	Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022 (GlobeNewswire)
09:00AM	Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-26-22 09:15AM	Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology (GlobeNewswire) -10.24%
Apr-19-22 09:15AM	Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil) (GlobeNewswire) +20.91%
Apr-01-22 07:00AM	Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights (GlobeNewswire) -6.41%
Mar-03-22 08:00AM	Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference (GlobeNewswire)
Feb-01-22 09:15AM	Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health (PR Newswire)
Jan-24-22 09:15AM	Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ (avanafil) to the United States (PR Newswire) +10.60%
Jan-18-22 09:20AM	Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug STENDRA® (avanafil) (PR Newswire) -11.45%
Jan-06-22 04:30PM	Petros Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference and the Biotech Showcase 2022 (PR Newswire)
Jan-05-22 01:38PM	Neville Rodie & Shaw Inc Buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk ... (GuruFocus.com) -9.15%
Dec-28-21 09:15AM	Petros Pharmaceuticals Announces Closing of $7.5 Million Offering (PR Newswire) +9.27%
Dec-22-21 09:10AM	Petros Pharmaceuticals Announces $7.5 Million Offering (PR Newswire) -18.34%
Dec-08-21 09:15AM	Petros Pharmaceuticals Announces Positive Over-the-Counter (OTC) Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA® (avanafil) (PR Newswire) +7.69%
Dec-02-21 12:00PM	Petros Pharmaceuticals Announces Closing of $10 Million Offering (PR Newswire) +10.68%
Nov-30-21 09:00AM	Petros Pharmaceuticals Announces $10 Million Offering (PR Newswire) -28.50%
Nov-15-21 04:30PM	Petros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update (PR Newswire) -22.02%
Nov-11-21 09:15AM	Petros Pharmaceuticals to Present at the Q4 Investor Summit Conference (PR Newswire)
Nov-08-21 09:15AM	Petros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease (PR Newswire)
Nov-03-21 09:16AM	Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. Generates 476% Year-Over-Year Growth of STENDRA Tablet Sales (PR Newswire) +64.57%
Oct-21-21 09:25AM	Petros Pharmaceuticals to Participate at Upcoming Benzinga Conference and Interview Show (PR Newswire)
Oct-19-21 09:25AM	Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering (PR Newswire)
Oct-14-21 09:00AM	Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering (PR Newswire)
Sep-23-21 08:30AM	Petros Pharmaceuticals to Present at the Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-10-21 08:30AM	Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-17-21 09:25AM	Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales (PR Newswire) -7.75%
Aug-16-21 08:30AM	Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021 (ACCESSWIRE) -10.26%
Aug-12-21 08:00AM	Petros Pharmaceuticals to Present at Two Upcoming August Conferences (PR Newswire)
Aug-11-21 10:39AM	Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit (Newsfile)
Jul-27-21 09:25AM	FDA Grants Meeting to Petros Pharmaceuticals to Discuss Label Expansion of Erectile Dysfunction Drug STENDRA® (PR Newswire)
Jul-13-21 09:15AM	Petros Pharmaceuticals Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment (PR Newswire)
Jul-12-21 08:15AM	Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021 (PR Newswire)
Jun-02-21 10:12AM	Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021 (PR Newswire)
May-17-21 08:22AM	Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales (PR Newswire) +5.74%
May-14-21 08:30AM	Petros Pharmaceuticals to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021 (PR Newswire)
May-07-21 08:00AM	Petros Pharmaceuticals to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021 (PR Newswire) +5.59%
Mar-18-21 09:00AM	Recently Published Research on Stendra®(avanafil) for Endothelial Function in Men with Erectile Dysfunction to Initiate Petros Pharmaceuticals' Plans for Expanded Labeling (PR Newswire)
Feb-18-21 08:00AM	Petros Pharmaceuticals Welcomes Dr. Mohit Khera to Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil) (PR Newswire) -9.22%
Feb-04-21 08:30AM	Petros Pharmaceuticals Establishes Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil) (PR Newswire)
Jan-19-21 08:00AM	Petros Pharmaceuticals to Participate in NobleCon17 (GlobeNewswire)
Dec-08-20 04:15PM	Neurotrope, Inc. Completes Independent Spin-off of Neurotrope Bioscience, Inc. and is Renamed Synaptogenix, Inc. (PR Newswire)

Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Petros Pharmaceuticals Inc

Upgrade your FINVIZ experience